Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours
Identifieur interne : 000067 ( Main/Exploration ); précédent : 000066; suivant : 000068Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours
Auteurs : RBID : ISTEX:259_1996_Article_BF01254466.pdfEnglish descriptors
Abstract
The purpose of this prospective study was to compare the ability of radiolabelled somatostatin analogue (RSA) and metaiodobenzylguanidine (MIBG) scintigraphy to display carcinoid tumours. Forty patients were studied after radiological assessment based on clinical symptomatology. These patients had radiologically demonstrated tumours (n=28), resected tumours discovered to be of the carcinoid type (n=5) or clinically and biologically suspected carcinoid tumours (n=7). They underwent indium-111 DTPA-pentetreotide or iodine-123-Tyr-3-octreotide and131I-MIBG scintigraphy. The results were compared with those of complementary surgical or morphological examinations and analysed according to the site of the tumour and the symptomatology. In the case of 31 patients with a total of 55 tumoral sites, the sensitivity of the initial radiological assessment, of RSA and of MIBG was 96%, 86% and 64%, respectively, for the detection of at least one tumour per patient, but 51%, 85% and 51%, respectively, for the total number of sites. No site was detected solely by MIBG. The concordance between RSA and MIBG was better when all sites were considered (kappa index+0.44) than for only extrahepatic abdominal tumoral sites (kappa index+0.095). Abdominal, thoracic or bone marrow tumours were more easily detected with RSA than with MIBG. Hepatic invasion (21 cases) was more easily detected by radiology (sensitivity 100%) than by RSA and MIBG, both of which displayed a sensitivity of 80%, but with differences in uptake intensity. Tumour detection using MIBG was more significantly linked with flush (P<0.01) than with diarrhoea (P>0.10). In the assessment of carcinoid tumours, RSA scintigraphy should be carried out initially (just after hepatic ultrasonography) and supplemented by MIBG, as comparison of the studies serves to guide therapeutic options and might be valuable for prognosis.
DOI: 10.1007/BF01254466
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title>Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours</title><author><name>Marie Nocaudie-Calzada</name><affiliation wicri:level="1"><mods:affiliation>Institut de Médecine Nucléaire et imagerie Fonctionnelle, CHRU de Lille, Lille, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Médecine Nucléaire et imagerie Fonctionnelle, CHRU de Lille, Lille</wicri:regionArea><placeName><region type="région">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name>Damien Huglo</name><affiliation wicri:level="1"><mods:affiliation>Institut de Médecine Nucléaire et imagerie Fonctionnelle, CHRU de Lille, Lille, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Médecine Nucléaire et imagerie Fonctionnelle, CHRU de Lille, Lille</wicri:regionArea><placeName><region type="région">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name>Bruno Carnaille</name><affiliation wicri:level="1"><mods:affiliation>Service de Chirurgie Générale et Endocrinienne, CHRU de Lille, Lille, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Chirurgie Générale et Endocrinienne, CHRU de Lille, Lille</wicri:regionArea><placeName><region type="région">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name>Charles Proye</name><affiliation wicri:level="1"><mods:affiliation>Service de Chirurgie Générale et Endocrinienne, CHRU de Lille, Lille, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Chirurgie Générale et Endocrinienne, CHRU de Lille, Lille</wicri:regionArea><placeName><region type="région">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name>Xavier Marchandise</name><affiliation wicri:level="1"><mods:affiliation>Institut de Médecine Nucléaire et imagerie Fonctionnelle, CHRU de Lille, Lille, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Médecine Nucléaire et imagerie Fonctionnelle, CHRU de Lille, Lille</wicri:regionArea><placeName><region type="région">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="RBID">ISTEX:259_1996_Article_BF01254466.pdf</idno><date when="1996">1996</date><idno type="doi">10.1007/BF01254466</idno><idno type="wicri:Area/Main/Corpus">000660</idno><idno type="wicri:Area/Main/Curation">000660</idno><idno type="wicri:Area/Main/Exploration">000067</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Carcinoid syndrome</term><term>Carcinoid tumour</term><term>Metaiodobenzylguanidine</term><term>Somatostatin</term><term>Tumour imaging</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">The purpose of this prospective study was to compare the ability of radiolabelled somatostatin analogue (RSA) and metaiodobenzylguanidine (MIBG) scintigraphy to display carcinoid tumours. Forty patients were studied after radiological assessment based on clinical symptomatology. These patients had radiologically demonstrated tumours (n=28), resected tumours discovered to be of the carcinoid type (n=5) or clinically and biologically suspected carcinoid tumours (n=7). They underwent indium-111 DTPA-pentetreotide or iodine-123-Tyr-3-octreotide and131I-MIBG scintigraphy. The results were compared with those of complementary surgical or morphological examinations and analysed according to the site of the tumour and the symptomatology. In the case of 31 patients with a total of 55 tumoral sites, the sensitivity of the initial radiological assessment, of RSA and of MIBG was 96%, 86% and 64%, respectively, for the detection of at least one tumour per patient, but 51%, 85% and 51%, respectively, for the total number of sites. No site was detected solely by MIBG. The concordance between RSA and MIBG was better when all sites were considered (kappa index+0.44) than for only extrahepatic abdominal tumoral sites (kappa index+0.095). Abdominal, thoracic or bone marrow tumours were more easily detected with RSA than with MIBG. Hepatic invasion (21 cases) was more easily detected by radiology (sensitivity 100%) than by RSA and MIBG, both of which displayed a sensitivity of 80%, but with differences in uptake intensity. Tumour detection using MIBG was more significantly linked with flush (P<0.01) than with diarrhoea (P>0.10). In the assessment of carcinoid tumours, RSA scintigraphy should be carried out initially (just after hepatic ultrasonography) and supplemented by MIBG, as comparison of the studies serves to guide therapeutic options and might be valuable for prognosis.</div></front></TEI><mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="71b7ec12d91e831741bb1441075ffad110fce903"><titleInfo lang="eng"><title>Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours</title></titleInfo><name type="personal"><namePart type="given">Marie</namePart><namePart type="family">Nocaudie-Calzada</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Institut de Médecine Nucléaire et imagerie Fonctionnelle, CHRU de Lille, Lille, France</affiliation></name><name type="personal"><namePart type="given">Damien</namePart><namePart type="family">Huglo</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Institut de Médecine Nucléaire et imagerie Fonctionnelle, CHRU de Lille, Lille, France</affiliation></name><name type="personal"><namePart type="given">Bruno</namePart><namePart type="family">Carnaille</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Service de Chirurgie Générale et Endocrinienne, CHRU de Lille, Lille, France</affiliation></name><name type="personal"><namePart type="given">Charles</namePart><namePart type="family">Proye</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Service de Chirurgie Générale et Endocrinienne, CHRU de Lille, Lille, France</affiliation></name><name type="personal"><namePart type="given">Xavier</namePart><namePart type="family">Marchandise</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Institut de Médecine Nucléaire et imagerie Fonctionnelle, CHRU de Lille, Lille, France</affiliation></name><typeOfResource>text</typeOfResource><genre>Original Article</genre><genre>Original Paper</genre><originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher><dateCreated encoding="w3cdtf">1996-02-15</dateCreated><dateValid encoding="w3cdtf">2005-02-17</dateValid><copyrightDate encoding="w3cdtf">1996</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="eng">The purpose of this prospective study was to compare the ability of radiolabelled somatostatin analogue (RSA) and metaiodobenzylguanidine (MIBG) scintigraphy to display carcinoid tumours. Forty patients were studied after radiological assessment based on clinical symptomatology. These patients had radiologically demonstrated tumours (n=28), resected tumours discovered to be of the carcinoid type (n=5) or clinically and biologically suspected carcinoid tumours (n=7). They underwent indium-111 DTPA-pentetreotide or iodine-123-Tyr-3-octreotide and131I-MIBG scintigraphy. The results were compared with those of complementary surgical or morphological examinations and analysed according to the site of the tumour and the symptomatology. In the case of 31 patients with a total of 55 tumoral sites, the sensitivity of the initial radiological assessment, of RSA and of MIBG was 96%, 86% and 64%, respectively, for the detection of at least one tumour per patient, but 51%, 85% and 51%, respectively, for the total number of sites. No site was detected solely by MIBG. The concordance between RSA and MIBG was better when all sites were considered (kappa index+0.44) than for only extrahepatic abdominal tumoral sites (kappa index+0.095). Abdominal, thoracic or bone marrow tumours were more easily detected with RSA than with MIBG. Hepatic invasion (21 cases) was more easily detected by radiology (sensitivity 100%) than by RSA and MIBG, both of which displayed a sensitivity of 80%, but with differences in uptake intensity. Tumour detection using MIBG was more significantly linked with flush (P<0.01) than with diarrhoea (P>0.10). In the assessment of carcinoid tumours, RSA scintigraphy should be carried out initially (just after hepatic ultrasonography) and supplemented by MIBG, as comparison of the studies serves to guide therapeutic options and might be valuable for prognosis.</abstract><subject lang="eng"><genre>Key words</genre><topic>Carcinoid tumour</topic><topic>Tumour imaging</topic><topic>Somatostatin</topic><topic>Metaiodobenzylguanidine</topic><topic>Carcinoid syndrome</topic></subject><relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title></titleInfo><titleInfo><title>European Journal of Nuclear Medicine</title><partNumber>Year: 1996</partNumber><partNumber>Volume: 23</partNumber><partNumber>Number: 11</partNumber></titleInfo><genre>Archive Journal</genre><originInfo><dateIssued encoding="w3cdtf">1996-11-01</dateIssued><copyrightDate encoding="w3cdtf">1996</copyrightDate></originInfo><subject usage="primary"><topic>Medicine & Public Health</topic><topic>Imaging / Radiology</topic><topic>Nuclear Medicine</topic></subject><identifier type="issn">0340-6997</identifier><identifier type="issn">Electronic: 1619-7089</identifier><identifier type="matrixNumber">259</identifier><identifier type="local">IssueArticleCount: 26</identifier><recordInfo><recordOrigin>Springer-Verlag, 1996</recordOrigin></recordInfo></relatedItem><identifier type="doi">10.1007/BF01254466</identifier><identifier type="matrixNumber">Art3</identifier><identifier type="local">BF01254466</identifier><accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition><accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition><accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition><accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition><accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition><accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition><part><extent unit="pages"><start>1448</start><end>1454</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1996</recordOrigin><recordIdentifier>259_1996_Article_BF01254466.pdf</recordIdentifier></recordInfo></mods></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000067 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000067 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:259_1996_Article_BF01254466.pdf
|texte= Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours
}}
| This area was generated with Dilib version V0.5.81. |  |